Stopping GLP-1 medication what happens
At IV DRIP Andover, we serve the health-conscious community of Andover, North Andover, and Lawrence with medical-grade infusions tailored to your lifestyle
Thus, in perfect agreement with the recent ADA-EASD consensus report [6], we also encourage the adoption of GLP-1RA plus SGLT2i combination therapy in T2DM patients with established ASCVD (coronary artery disease, cerebrovascular disease, or peripheral arterial disease) or multiple risk factors for ASCVD (i.e., age 55 years, obesity, dyslipidemia, hypertension, current tobacco use, left ventricular hypertrophy, and/or proteinuria) whose HbA1c remains suboptimal despite initial treatment with only one of these agents
Our team can't stress this enough: your tools are an extension of your methodology
Oscar's Medicare footprint is small